Search results for " HIV infection"

showing 10 items of 46 documents

A novel methodology for large-scale phylogeny partition

2011

Understanding the determinants of virus transmission is a fundamental step for effective design of screening and intervention strategies to control viral epidemics. Phylogenetic analysis can be a valid approach for the identification of transmission chains, and very-large data sets can be analysed through parallel computation. Here we propose and validate a new methodology for the partition of large-scale phylogenies and the inference of transmission clusters. This approach, on the basis of a depth-first search algorithm, conjugates the evaluation of node reliability, tree topology and patristic distance analysis. The method has been applied to identify transmission clusters of a phylogeny …

Genetics and Molecular Biology (all)MalepolTheoretical computer scienceInferenceGene Products polGeneral Physics and AstronomyHIV InfectionsBiologyNetwork topologySettore MED/17 - MALATTIE INFETTIVEBiochemistryArticleGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciencesPhysics and Astronomy (all)0302 clinical medicineSearch algorithmphylogenetic analysis; virus transmissionGene ProductsHumansHIV Infection030212 general & internal medicinePhylogeny030304 developmental biologyAlgorithms; Classification; Female; Gene Products pol; HIV Infections; HIV-1; Humans; Male; Phylogeny; Biochemistry Genetics and Molecular Biology (all); Chemistry (all); Physics and Astronomy (all)Genetics0303 health sciencesBiochemistry Genetics and Molecular Biology (all)MultidisciplinaryPhylogenetic treeNode (networking)phylogenetic analysisChemistry (all)HIVGeneral Chemistryvirus transmissionClassificationPartition (database)AlgorithmIdentification (information)Transmission (telecommunications)HIV-1FemaleMETHODOLOGYAlgorithmsHumanNature Communications
researchProduct

Perceptions of U = U Among Italian Infectious Diseases Specialists: A Nationwide Survey on Providers' Attitudes Toward the Risk of HIV Transmission i…

2022

This survey aimed to understand how far the Italian infectious diseases (ID) specialists are confident in the "Undetectable = Untransmittable" (U = U) message and translate this concept into clinical practice. An anonymous survey was distributed by e-mail to 286 clinicians to collect their opinions regarding six situations potentially at risk of HIV transmission between virologically suppressed patients and seronegative individuals who possibly require postexposure prophylaxis (PEP). Overall, 51% of ID specialists deemed zero risk of HIV transmission through condomless sex for undetectable patients. This answer was more frequent among HIV specialists (30% vs. 21%, p = .01) and clinicians wo…

HIV; HIV providers; PEP; U = U; survey; Humans; Surveys and Questionnaires; Attitude; RNA; Anti-HIV Agents; HIV Infections; PhysiciansSettore MED/17 - Malattie InfettiveAnti-HIV AgentsImmunologyAnti-HIV AgentHIVHIV InfectionsHIV providersInfectious DiseasesAttitudeSurveys and QuestionnairesPhysiciansVirologyPEPHIV providerSurveys and QuestionnaireHumansRNAHIV InfectionsurveyU = UHumanAIDS Research and Human Retroviruses
researchProduct

Fever with perinasal and tongue lesions: A diagnostic challenge

2023

The diagnosis may be challenging, and high suspicion index should be maintained in immunosuppressed patients with unusual mucocutaneous lesions, even in non-endemic areas for mucocutaneous leishmaniasis.

Infectious DiseasesPublic Health Environmental and Occupational HealthLeishmaniasis HIV infection
researchProduct

From current status to optimization of HCV treatment: Recommendations from an expert panel

2016

Chronic hepatitis C virus (HCV) infection is a major public health problem at a global level, causing an enormous burden of hepatic and extra-hepatic morbidity and mortality. Treatment of chronic HCV (CHC) has been revolutionized in the last few years by the introduction of highly effective and well tolerated direct acting antiviral agents (DAAs) able to achieve >90% rates of sustained virological response (SVR) in many groups of patients, including those previously excluded from interferon-based regimens. For such reason interferon-free regimens are now the treatments of choice for all patients. Successful anti-HCV treatment can stop liver disease progression and can solve the HCV-relat…

Liver CirrhosisDirect-acting antiviral agentmedicine.medical_treatmentResistanceAntiviral therapy; Cirrhosis; Direct-acting antiviral agents; HCV; Hepatitis C; Liver transplantation; Resistance; Antiviral Agents; Carcinoma Hepatocellular; Coinfection; Drug Therapy Combination; HIV Infections; Hepacivirus; Hepatitis C Chronic; Humans; Interferon-alpha; Italy; Liver Cirrhosis; Liver Neoplasms; Practice Guidelines as Topic; Ribavirin; Societies Medical; Viral Load; Hepatology; GastroenterologyHIV InfectionsHepacivirusAntiviral therapy; Cirrhosis; Direct-acting antiviral agents; HCV; Hepatitis C; Liver transplantation; Resistance; Hepatology; GastroenterologyLiver transplantationAntiviral therapyLiver disease0302 clinical medicineHIV Infection030212 general & internal medicineChronicSocieties MedicalCoinfectionLiver NeoplasmsGastroenterologyHepatitis CViral LoadSettore MED/07 - Microbiologia e Microbiologia ClinicaHepatitis CItalyCirrhosisLiver NeoplasmCombinationPractice Guidelines as TopicHCV030211 gastroenterology & hepatologyDrug Therapy CombinationViral loadHumanAntiviral therapy; Cirrhosis; Direct-acting antiviral agents; HCV; Hepatitis C; Liver transplantation; Resistancemedicine.medical_specialtyCarcinoma HepatocellularLiver CirrhosiAlpha interferonAntiviral therapy; Cirrhosis; Direct-acting antiviral agents; HCV; Hepatitis C; Liver transplantation; Resistance; Antiviral Agents; Carcinoma Hepatocellular; Coinfection; Drug Therapy Combination; HIV Infections; Hepacivirus; Hepatitis C Chronic; Humans; Interferon-alpha; Italy; Liver Cirrhosis; Liver Neoplasms; Practice Guidelines as Topic; Ribavirin; Societies Medical; Viral LoadAntiviral Agents03 medical and health sciencesDrug TherapyMedicalInternal medicineRibavirinmedicineHumansIntensive care medicineAntiviral AgentCirrhosiHepaciviruLiver transplantationHepatologybusiness.industryPublic healthCarcinomaInterferon-alphaHepatocellularHepatologyHepatitis C Chronicmedicine.diseaseSurgeryPosition paperDirect-acting antiviral agentsSocietiesbusiness
researchProduct

Human Immunodeficiency Virus Continuum of Care in 11 European Union Countries at the End of 2016 Overall and by Key Population: Have We Made Progress?

2020

Abstract Background High uptake of antiretroviral treatment (ART) is essential to reduce human immunodeficiency virus (HIV) transmission and related mortality; however, gaps in care exist. We aimed to construct the continuum of HIV care (CoC) in 2016 in 11 European Union (EU) countries, overall and by key population and sex. To estimate progress toward the Joint United Nations Programme on HIV/AIDS (UNAIDS) 90-90-90 target, we compared 2016 to 2013 estimates for the same countries, representing 73% of the population in the region. Methods A CoC with the following 4 stages was constructed: number of people living with HIV (PLHIV); proportion of PLHIV diagnosed; proportion of those diagnosed …

Male0301 basic medicinePsychological interventionHuman immunodeficiency virus (HIV)MedizinContinuum of care; Europe; HIV infection; Key population; Sex; Anti-Retroviral Agents; Continuity of Patient Care; European Union; HIV; Humans; Male; HIV InfectionsHIV InfectionsContinuum of care; Europe; HIV infection; Key population; Sexmedicine.disease_causekey population0302 clinical medicineContinuum of careHIV Infection030212 general & internal medicineMen having sex with menContinuum of caremedia_commoneducation.field_of_study[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyTransmission (medicine)Continuity of Patient CareEuropeInfectious DiseasesAcademicSubjects/MED00290Anti-Retroviral AgentsHIV infection continuum of care sex key population EuropeSexMicrobiology (medical)PopulationSocio-culturale03 medical and health sciencesAcquired immunodeficiency syndrome (AIDS)SDG 3 - Good Health and Well-beingmedicinemedia_common.cataloged_instanceHumansEuropean UnionEuropean unioneducationPandemicsHIV infection ; continuum of care ; sex ; key population ; Europebusiness.industrySARS-CoV-2COVID-19HIVmedicine.diseaseHIV infectioncontinuum of care030112 virologyMajor Articles and CommentariesKey populationAnti-Retroviral Agentbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyDemography
researchProduct

Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection?

2019

AbstractBackgroundAlcohol consumption is a known risk factor for liver disease in HIV-infected populations. Therefore, knowledge of alcohol consumption behaviour and risk of disease progression associated with hazardous drinking are important in the overall management of HIV disease. We aimed at assessing the usefulness of routine data collected on alcohol consumption in predicting risk of severe liver disease (SLD) among people living with HIV (PLWHIV) with or without hepatitis C infection seen for routine clinical care in Italy.MethodsWe included PLWHIV from two observational cohorts in Italy (ICONA and HepaICONA). Alcohol consumption was assessed by physician interview and categorized ac…

Male030508 substance abuseHIV InfectionsSeverity of Illness IndexCohort StudiesLiver disease0302 clinical medicineRisk FactorsEpidemiologyMedicineHIV InfectionAlcohol consumptionAlcohol consumption HIV-infected HIV/HCV co-infection Severe liver disease030212 general & internal medicineeducation.field_of_studyCoinfectionLiver Diseaselcsh:Public aspects of medicineLiver DiseasesHazard ratioHepatitis CMiddle AgedHepatitis CItalyalcohol consumption; HIV-infected; HIV/HCV co-infection; severe liver diseaseCoinfectionFemale0305 other medical scienceHumanCohort studyResearch ArticleAdultmedicine.medical_specialtyAlcohol DrinkingPopulationSevere liver diseaseHIV/HCV co-infectionNO03 medical and health sciencesEnvironmental healthHumansRisk factorAlcohol consumption; HIV-infected; HIV/HCV co-infection; Severe liver disease; Adult; Alcohol Drinking; Cohort Studies; Female; HIV Infections; Hepatitis C; Humans; Italy; Liver Diseases; Male; Middle Aged; Risk Factors; Severity of Illness Index; CoinfectioneducationHIV-infectedbusiness.industryRisk FactorPublic Health Environmental and Occupational Healthlcsh:RA1-1270medicine.diseaseCohort StudiebusinessBMC Public Health
researchProduct

Effect of cytomegalovirus-induced immune response, self antigen-induced immune response, and microbial translocation on chronic immune activation in …

2013

International audience; We evaluated the impact of cytomegalovirus (CMV)-induced immune responses, autoimmune-induced immune responses, and microbial translocation on immune activation in 191 human immunodeficiency virus type 1-infected patients from the ANRS CO3 Aquitaine Cohort. All enrolled subjects had achieved long-term virological suppression during receipt of combination antiretroviral therapy (cART). HLA-DR(+)/CD38(+) expression was 16.8% among CD8(+) T cells. Independent of age, CD4(+) T-cell count, 16S ribosomal DNA load, and regulatory T-cell count, positive results of Quantiferon CMV analysis (P = .02), positive results of CMV-pp65 enzyme-linked immunosorbent spot analysis (P = …

MaleCytomegalovirusAutoimmunityHIV InfectionsCD8-Positive T-LymphocytesCD38Lymphocyte Activationmedicine.disease_causeAutoimmunityCohort Studies0302 clinical medicine[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases[ SDV.MP ] Life Sciences [q-bio]/Microbiology and ParasitologyAntiretroviral Therapy Highly ActiveImmunology and Allergy030212 general & internal medicineMESH: Cytomegalovirus Infections/immunologyMESH: HLA-DR Antigens/metabolismMESH: Cohort Studies0303 health sciencesMESH: HIV Infections/drug therapyvirus diseasesViral Load3. Good healthInfectious Diseases[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologyMESH: CD8-Positive T-Lymphocytes/immunologyCytomegalovirus Infections[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases[SDV.IMM]Life Sciences [q-bio]/ImmunologyFemaleFranceMESH: Cytomegalovirus/immunologyMESH: Viral Load[SDV.IMM] Life Sciences [q-bio]/ImmunologyCongenital cytomegalovirus infectionHuman leukocyte antigenBiologyQuantiFERONViral Matrix Proteins03 medical and health sciencesImmune systemMESH: Cross-Sectional StudiesAntigenMESH: AutoimmunitymedicineHumansMESH: Phosphoproteins/immunology[SDV.MP] Life Sciences [q-bio]/Microbiology and ParasitologyMESH: Viral Matrix Proteins/immunology030304 developmental biologyMESH: HumansMESH: HIV-1/geneticsMESH: HIV-1/physiologyMESH: HIV Infections/immunologyHLA-DR AntigensPhosphoproteinsmedicine.diseaseVirologyMESH: MaleMESH: Lymphocyte Activation/immunologyMESH: FranceCross-Sectional Studies[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologieImmunologyHIV-1[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieMESH: HIV-1/drug effectsMESH: FemaleCD8
researchProduct

Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study

2011

Background and objectives: Guidelines indicate a plasma HIV-1 RNA load of 500-1000 copies/mL as the minimal threshold for antiretroviral drug resistance testing. Resistance testing at lower viral load levels may be useful to guide timely treatment switches, although data on the clinical utility of this remain limited. We report here the influence of viral load levels on the probability of detecting drug resistance mutations (DRMs) and other mutations by routine genotypic testing in a large multicentre European cohort, with a focus on tests performed at a viral load <1000 copies/mL. Methods: A total of 16511 HIV-1 reverse transcriptase and protease sequences from 11492 treatment-experienced …

MaleDrug ResistanceHIV InfectionsDrug resistanceCohort Studies0302 clinical medicineGenotypeHIV InfectionPharmacology (medical)030212 general & internal medicineViral0303 health sciencesProteolytic enzymesGenotypic testing; HIV; Viral load; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Europe; Female; Genotype; HIV Infections; HIV-1; Humans; Male; RNA Viral; Viral Proteins; Drug Resistance Viral; Mutation Missense; Viral Load; Pharmacology; Pharmacology (medical); Infectious DiseasesViral LoadGenotypic testing3. Good healthEuropeInfectious DiseasesCohortRNA ViralFemaleViral loadCohort studyHumanMicrobiology (medical)AdultGenotypeAnti-HIV AgentsMutation MissenseBiologySettore MED/17 - MALATTIE INFETTIVE03 medical and health sciencesViral ProteinsSDG 3 - Good Health and Well-beingDrug Resistance ViralHumansViral ProteinPharmacology030306 microbiologyHIVAnti-HIV AgentVirologyReverse transcriptaseCD4 Lymphocyte CountRegimenHIV; genotypic testing; viral loadGenotypic testing; HIV; Viral load; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Drug Resistance Viral; Europe; Female; Genotype; HIV Infections; HIV-1; Humans; Male; Mutation Missense; RNA Viral; Viral Load; Viral ProteinsImmunologyMutationHIV-1RNAMissenseCohort Studie
researchProduct

Evolving clinical landscape of chronic hepatitis B: A multicenter Italian study

2009

The aim of the study was to evaluate the characteristics of chronic hepatitis B with special reference to the geographical origin of the patients and to the prevalence of HBeAg and viral and non-viral co-factors of liver disease. A cross-sectional multicenter survey was undertaken, which enrolled 1,386 HBsAg chronic carriers observed consecutively in 21 referral centers over a 6-month period. The prevalence of HBeAg in patients was 11%; the presence of HBeAg was associated independently with a younger age and co-infection with HIV. Anti-HDV, anti-HCV, or anti-HIV antibodies were detected in 8.1%, 6.5%, and 2%, respectively. However, among the patients first diagnosed during the study period…

MaleHBsAgvirusesHIV InfectionsAntibodies ViralHBeAgHepatitisLiver diseaseCHRONIC HEPATITIS B; HBsAg; epidemiology; GEOGRAPHICAL LANDSCAPEHBsAg0302 clinical medicine80 and overPrevalenceViralChronicAged 80 and over0303 health sciencesGeographyAge Factorsvirus diseasesHepatitis CHepatitis BMiddle AgedHepatitis BHepatitis D3. Good healthInfectious DiseasesHBeAgCirrhosisItalyMedicineepidemiology030211 gastroenterology & hepatologyFemaleHepatitis D virusHumanAdultHepatitis Viral HumanAdolescentCHRONIC HEPATITIS BAntibodies03 medical and health sciencesHepatitis B ChronicHDVVirologyCirrhosis HBeAg HDV Hepatitis B Adolescent Adult Age Factors Aged Aged 80 and over Antibodies Viral Cross-Sectional Studies Female Geography HIV HIV Infections Hepatitis B Chronic Hepatitis Viral Human Humans Italy Male Middle Aged Prevalence Virology Infectious DiseasesmedicineCirrhosis; HBeAg; HDV; Hepatitis B; Adolescent; Adult; Age Factors; Aged; Aged 80 and over; Antibodies Viral; Cross-Sectional Studies; Female; Geography; HIV; HIV Infections; Hepatitis B Chronic; Hepatitis Viral Human; Humans; Italy; Male; Middle Aged; Prevalence; Infectious Diseases; VirologyHumans030304 developmental biologyAgedHepatitisCirrhosibusiness.industryHIVmedicine.diseaseVirologydigestive system diseasesCross-Sectional StudiesGEOGRAPHICAL LANDSCAPEbusiness
researchProduct

No pol mutation is associated independently with the lack of immune recovery in patients infected with HIV and failing antiretroviral therapy

2011

An investigation was undertaken to determine whether specific pol mutations hinder long-term immune recovery regardless of virological response. In total, 826 patients with >50 HIV RNA copies/ml, who underwent genotypic resistance testing between 1 January 2000 and 31 December 2003 after >3 years of antiretroviral treatment, and were followed up for >3 years after genotypic resistance testing, were analyzed retrospectively. The outcome of the study was the lack of immune recovery after >3 years of follow-up, defined as a slope by linear regression 50 copies/ml divided by the number of HIV RNA measurements during follow-up. Logistic regression was used for univariable and multivariable analy…

MaleHIV InfectionsDrug resistanceLogistic regressionResistance to nucleoside reverse transcriptase inhibitorCD4+ T-lymphocyteRetrospective StudieImmunopathologyAntiretroviral Therapy Highly ActiveResistance to non-nucleoside reverse transcriptase inhibitorgeneticsResistance to protease inhibitorHIV Infectionresistance to nucleoside reverse transcriptase inhibitorsViralSidaresistance to protease inhibitorsbiologyReverse-transcriptase inhibitorViral LoadGenes poldrug therapy/immunology/virologyReverse Transcriptase InhibitorInfectious DiseasesTreatment Outcomeresistance to non-nucleoside reverse transcriptase inhibitorsReverse Transcriptase InhibitorsFemaleViral loadmedicine.drugHumanpolAnti-HIV AgentsAntiretroviral TherapyViremiaInfectious DiseaseSettore MED/17 - MALATTIE INFETTIVEpharmacology/therapeutic useAcquired immunodeficiency syndrome (AIDS)VirologyDrug Resistance ViralmedicineHumansHighly ActiveRetrospective StudiesAnti-HIV Agents; pharmacology/therapeutic use Antiretroviral Therapy; Highly Active CD4 Lymphocyte Count Drug Resistance; Viral; genetics Female Genes; pol HIV Infections; drug therapy/immunology/virology HIV-1; drug effects/enzymology/genetics Humans Male Mutation Retrospective Studies Reverse Transcriptase Inhibitors; therapeutic use Treatment Outcome Viral Loaddrug resistanceAnti-HIV Agentbiology.organism_classificationmedicine.diseaseVirologyCD4 Lymphocyte CountGenesdrug effects/enzymology/geneticstherapeutic useMutationCD4+ T-lymphocytesHIV-1
researchProduct